Literature DB >> 24165727

Mining the epigenetic landscape in ALL.

Lindsay M Lafave1, Ross L Levine.   

Abstract

The significance of epigenomic aberrations in cancer development has been underscored by the discovery of mutations in key chromatin modifiers, most notably in hematological malignancies. A new study of pediatric acute lymphoblastic leukemia (ALL) demonstrates the usefulness of mapping global epigenetic signatures and applying these data in a framework to identify and characterize underlying somatic genetic alterations in human cancers.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24165727     DOI： 10.1038/ng.2808

Source DB:  PubMed          Journal:  Nat Genet        ISSN： 1061-4036            Impact factor:   38.330


  15 in total

1.  NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15).

Authors:  Roberto Rosati; Roberta La Starza; Angelo Veronese; Ana Aventin; Christine Schwienbacher; Teresa Vallespi; Massimo Negrini; Massimo F Martelli; Cristina Mecucci
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

2.  Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.

Authors:  Damian B Yap; Justin Chu; Tobias Berg; Matthieu Schapira; S-W Grace Cheng; Annie Moradian; Ryan D Morin; Andrew J Mungall; Barbara Meissner; Merrill Boyle; Victor E Marquez; Marco A Marra; Randy D Gascoyne; R Keith Humphries; Cheryl H Arrowsmith; Gregg B Morin; Samuel A J R Aparicio
Journal:  Blood       Date:  2010-12-29       Impact factor: 22.113

3.  The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells.

Authors:  Eva Martinez-Garcia; Relja Popovic; Dong-Joon Min; Steve M M Sweet; Paul M Thomas; Leonid Zamdborg; Aaron Heffner; Christine Will; Laurence Lamy; Louis M Staudt; David L Levens; Neil L Kelleher; Jonathan D Licht
Journal:  Blood       Date:  2010-10-25       Impact factor: 22.113

4.  EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.

Authors:  Michael T McCabe; Heidi M Ott; Gopinath Ganji; Susan Korenchuk; Christine Thompson; Glenn S Van Aller; Yan Liu; Alan P Graves; Anthony Della Pietra; Elsie Diaz; Louis V LaFrance; Mark Mellinger; Celine Duquenne; Xinrong Tian; Ryan G Kruger; Charles F McHugh; Martin Brandt; William H Miller; Dashyant Dhanak; Sharad K Verma; Peter J Tummino; Caretha L Creasy
Journal:  Nature       Date:  2012-10-10       Impact factor: 49.962

5.  A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.

Authors:  Sarah K Knutson; Tim J Wigle; Natalie M Warholic; Christopher J Sneeringer; Christina J Allain; Christine R Klaus; Joelle D Sacks; Alejandra Raimondi; Christina R Majer; Jeffrey Song; Margaret Porter Scott; Lei Jin; Jesse J Smith; Edward J Olhava; Richard Chesworth; Mikel P Moyer; Victoria M Richon; Robert A Copeland; Heike Keilhack; Roy M Pollock; Kevin W Kuntz
Journal:  Nat Chem Biol       Date:  2012-09-30       Impact factor: 15.040

6.  H3K36 methylation antagonizes PRC2-mediated H3K27 methylation.

Authors:  Wen Yuan; Mo Xu; Chang Huang; Nan Liu; She Chen; Bing Zhu
Journal:  J Biol Chem       Date:  2011-01-14       Impact factor: 5.157

7.  A novel gene, NSD1, is fused to NUP98 in the t(5;11)(q35;p15.5) in de novo childhood acute myeloid leukemia.

Authors:  R J Jaju; C Fidler; O A Haas; A J Strickson; F Watkins; K Clark; N C Cross; J F Cheng; P D Aplan; L Kearney; J Boultwood; J S Wainscoat
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

8.  NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming.

Authors:  Alex J Kuo; Peggie Cheung; Kaifu Chen; Barry M Zee; Mitomu Kioi; Josh Lauring; Yuanxin Xi; Ben Ho Park; Xiaobing Shi; Benjamin A Garcia; Wei Li; Or Gozani
Journal:  Mol Cell       Date:  2011-11-18       Impact factor: 17.970

9.  TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis.

Authors:  S A Shurtleff; A Buijs; F G Behm; J E Rubnitz; S C Raimondi; M L Hancock; G C Chan; C H Pui; G Grosveld; J R Downing
Journal:  Leukemia       Date:  1995-12       Impact factor: 11.528

10.  EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency.

Authors:  Xiaohua Shen; Yingchun Liu; Yu-Jung Hsu; Yuko Fujiwara; Jonghwan Kim; Xiaohong Mao; Guo-Cheng Yuan; Stuart H Orkin
Journal:  Mol Cell       Date:  2008-11-21       Impact factor: 17.970
View more
  2 in total

1.  An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia.

Authors:  Alok Swaroop; Jon A Oyer; Christine M Will; Xiaoxiao Huang; Wenbo Yu; Catalina Troche; Marinka Bulic; Benjamin H Durham; Qiang Jeremy Wen; John D Crispino; Alexander D MacKerell; Richard L Bennett; Neil L Kelleher; Jonathan D Licht
Journal:  Oncogene       Date:  2018-08-31       Impact factor: 9.867

Review 2.  Omics Biomarkers in Obesity: Novel Etiological Insights and Targets for Precision Prevention.

Authors:  Krasimira Aleksandrova; Caue Egea Rodrigues; Anna Floegel; Wolfgang Ahrens
Journal:  Curr Obes Rep       Date:  2020-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.